TY  - JOUR
A1  - Schick, Martin Alexander
A1  - Schlegel, Nicolas
T1  - Clinical implication of phosphodiesterase-4-inhibition
T2  - International Journal of Molecular Sciences
N2  - The pleiotropic function of 3′,5′-cyclic adenosine monophosphate (cAMP)-dependent pathways in health and disease led to the development of pharmacological phosphodiesterase inhibitors (PDE-I) to attenuate cAMP degradation. While there are many isotypes of PDE, a predominant role of PDE4 is to regulate fundamental functions, including endothelial and epithelial barrier stability, modulation of inflammatory responses and cognitive and/or mood functions. This makes the use of PDE4-I an interesting tool for various therapeutic approaches. However, due to the presence of PDE4 in many tissues, there is a significant danger for serious side effects. Based on this, the aim of this review is to provide a comprehensive overview of the approaches and effects of PDE4-I for different therapeutic applications. In summary, despite many obstacles to use of PDE4-I for different therapeutic approaches, the current data warrant future research to utilize the therapeutic potential of phosphodiesterase 4 inhibition.
KW  - phosphodiesterase
KW  - phosphodiesterase-4
KW  - phosphodiesterase-inhibitors
KW  - PDE
KW  - PDE4-I
Y1  - 2022
UR  - https://opus.bibliothek.uni-wuerzburg.de/frontdoor/index/index/docId/28451
UR  - https://nbn-resolving.org/urn:nbn:de:bvb:20-opus-284511
SN  - 1422-0067
VL  - 23
IS  - 3
ER  -